Cilengitide targeting of αvβ3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 62; no. 15; pp. 4263 - 4272
Main Authors BURKE, Patricia A, DENARDO, Sally J, MIERS, Laird A, LAMBORN, Kathleen R, MATZKU, Siegfried, DENARDO, Gerald L
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 01.08.2002
Subjects
Antineoplastic agents
Biological and medical sciences
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
Medical sciences
Pharmacology. Drug treatments
Adenocarcinoma
Antineoplastic agent
Potentiation
Targeting
Peptides
Immunoradiotherapy
Mammary gland
Antiangiogenic agent
Biological receptor
Human
Treatment efficiency
Rodentia
Malignant tumor
Mammary gland diseases
Integrin αvβ3
Vertebrata
Chemotherapy
Mammalia
Treatment
Mouse
Cell death
Animal
Cilengitide
Combined treatment
Apoptosis
Online AccessGet full text

Cover

More Information
ISSN:0008-5472
1538-7445